Published in Medical Device Business Week, April 7th, 2004
Anastrozole, one of several selective aromatase inhibitors under study, has already been shown, through the 9,366 patient ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial, to provide significant efficacy benefits compared with tamoxifen, in addition to a more favorable overall tolerability profile in the adjuvant treatment of postmenopausal women with early breast cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week